finance.yahoo.com
Neutralfinance.yahoo.com ·
Eli Lilly Lly Stock Trades
MedicalHistoricTradeHealth Technologies
Topic context
This topic has been covered 373847 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEli Lilly's $4.5B capex expands capacity for weight-loss drugs (GLP-1s), addressing demand for new pill Foundayo. Revenue growth and raised guidance signal strong pricing power and margin expansion. Impact is company-specific but reflects broader pharma sector trend in obesity drug market.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Eli Lilly announced $4.5 billion investment to expand U.S. manufacturing capabilities.
- Total investment in Indiana reaches $21 billion since 2020.
- First-quarter 2026 revenue grew 56% to $19.8 billion.
- Raised full-year revenue forecast to $82-$85 billion.
- GLP-1 drugs Mounjaro and Zepbound drive strong sales.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
fool.com
Canaan Can Q1 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
zerohedge.com
New Fed Chair Pledges Regime Change Fight Inflation Heres What Could Mean Practice
finance.yahoo.com